Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 458

1.

hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.

Giunco S, Dolcetti R, Keppel S, Celeghin A, Indraccolo S, Dal Col J, Mastorci K, De Rossi A.

Clin Cancer Res. 2013 Apr 15;19(8):2036-47. doi: 10.1158/1078-0432.CCR-12-2537. Epub 2013 Feb 26.

2.

hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.

Terrin L, Dolcetti R, Corradini I, Indraccolo S, Dal Col J, Bertorelle R, Bonaldi L, Esposito G, De Rossi A.

Int J Cancer. 2007 Aug 1;121(3):576-87.

3.

Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.

Giunco S, Celeghin A, Gianesin K, Dolcetti R, Indraccolo S, De Rossi A.

Cell Death Dis. 2015 May 28;6:e1774. doi: 10.1038/cddis.2015.145.

4.

Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.

Seo JS, Cho NY, Kim HR, Tsurumi T, Jang YS, Lee WK, Lee SK.

Oncol Rep. 2008 Jan;19(1):93-8.

PMID:
18097580
5.

Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.

Hsu CH, Hergenhahn M, Chuang SE, Yeh PY, Wu TC, Gao M, Cheng AL.

Anticancer Res. 2002 Nov-Dec;22(6C):4065-71.

PMID:
12553034
6.
7.
8.

Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.

Celeghin A, Giunco S, Freguja R, Zangrossi M, Nalio S, Dolcetti R, De Rossi A.

Cell Death Dis. 2016 Dec 29;7(12):e2562. doi: 10.1038/cddis.2016.425.

9.

TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.

Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D.

Oncogene. 2010 Aug 12;29(32):4588-98. doi: 10.1038/onc.2010.203. Epub 2010 May 31.

PMID:
20514021
10.

Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.

Blood. 1995 Jul 15;86(2):659-65.

11.

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Feng WH, Hong G, Delecluse HJ, Kenney SC.

J Virol. 2004 Feb;78(4):1893-902.

12.

Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.

Westphal EM, Mauser A, Swenson J, Davis MG, Talarico CL, Kenney SC.

Cancer Res. 1999 Apr 1;59(7):1485-91.

13.
14.

Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.

Rechsteiner MP, Berger C, Weber M, Sigrist JA, Nadal D, Bernasconi M.

J Gen Virol. 2007 May;88(Pt 5):1454-9.

PMID:
17412973
15.

Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.

Kraus RJ, Yu X, Cordes BA, Sathiamoorthi S, Iempridee T, Nawandar DM, Ma S, Romero-Masters JC, McChesney KG, Lin Z, Makielski KR, Lee DL, Lambert PF, Johannsen EC, Kenney SC, Mertz JE.

PLoS Pathog. 2017 Jun 15;13(6):e1006404. doi: 10.1371/journal.ppat.1006404. eCollection 2017 Jun.

16.

Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells.

Al Tabaa Y, Tuaillon E, Bollore K, Foulongne V, Petitjean G, Seigneurin JM, Duperray C, Desgranges C, Vendrell JP.

Blood. 2009 Jan 15;113(3):604-11. doi: 10.1182/blood-2008-02-136903. Epub 2008 Oct 9.

18.

Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.

Ghosh SK, Forman LW, Akinsheye I, Perrine SP, Faller DV.

Blood Cells Mol Dis. 2007 Jan-Feb;38(1):57-65. Epub 2006 Dec 11.

19.

Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells.

Kuhn-Hallek I, Sage DR, Stein L, Groelle H, Fingeroth JD.

Blood. 1995 Mar 1;85(5):1289-99.

20.

Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.

Gorres KL, Daigle D, Mohanram S, McInerney GE, Lyons DE, Miller G.

MBio. 2016 Mar 1;7(2):e00113. doi: 10.1128/mBio.00113-16.

Supplemental Content

Support Center